In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...
On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...
GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...
The Federal Trade Commission has challenged a private equity firm’s attempt to buy Surmodics for approximately $627 million, ...
The Federal Trade Commission has filed a lawsuit to block private equity firm GTCR BC Holdings from acquiring Surmodics, a medical technology company, arguing the deal would reduce competition for ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.